Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Moxonidine: a review

S T Morris1, J L Reid

  • 1Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, UK.

Journal of Human Hypertension
|December 24, 1997
PubMed
Summary
This summary is machine-generated.

Moxonidine, a novel imidazoline compound, lowers blood pressure by acting on central I1 receptors, potentially offering fewer side effects than older drugs. Its clinical effectiveness and safety profile require further evaluation for hypertension management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood pressure in genetically hypertensive rats. Influence of the Y chromosome.

Hypertension (Dallas, Tex. : 1979)·1995
Same author

Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.

Arteriosclerosis, thrombosis, and vascular biology·1995
Same author

Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy.

Journal of human hypertension·1995
Same author

Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.

Annals of the New York Academy of Sciences·1995
Same author

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II.

Journal of human hypertension·1995
Same author

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man.

Journal of cardiovascular pharmacology·1995
Same journal

Previous COVID-19 infection: An overlooked cardiovascular risk factor.

Journal of human hypertension·2026
Same journal

Patient out-of-pocket costs for antihypertensive single pill combination products with cost caps.

Journal of human hypertension·2026
Same journal

Mindfulness based interventions for blood pressure reduction: systematic and umbrella review of existing meta-analyses.

Journal of human hypertension·2026
Same journal

Invasive observation of reactive systolic blood pressure responses to upper-arm cuff inflation.

Journal of human hypertension·2026
Same journal

Association between post-thrombectomy blood pressure trajectories and clinical outcomes in hypertensive patients with acute ischemic stroke: a retrospective cohort study.

Journal of human hypertension·2026
Same journal

Systemic inflammation indices generated from first-trimester blood tests can be potential biomarkers for predicting preeclampsia.

Journal of human hypertension·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Therapeutics

Background:

  • Moxonidine is an imidazoline compound targeting central I1 imidazoline receptors.
  • It is proposed to reduce blood pressure via a novel mechanism.
  • This mechanism is claimed to result in fewer adverse effects compared to older centrally-acting antihypertensives like clonidine.

Purpose of the Study:

  • To review the pharmacology of moxonidine.
  • To assess its clinical pharmacokinetics and efficacy as an antihypertensive.
  • To evaluate its adverse effect profile and compare it with existing antihypertensive drugs.

Main Methods:

  • Review of existing literature on moxonidine.
  • Analysis of pharmacological data.

Related Experiment Videos

  • Examination of clinical pharmacokinetic studies.
  • Evaluation of comparative efficacy and safety studies.

    • Main Results:

    • Moxonidine acts on central I1 imidazoline receptors to lower blood pressure.
    • The drug's pharmacology, pharmacokinetics, and adverse effect profile were examined.
    • Comparative studies with existing antihypertensive agents were considered.

    Conclusions:

    • Moxonidine's novel mechanism may offer an advantage in terms of side effects.
    • Its overall clinical utility in hypertension management remains to be definitively established.
    • Further evidence is needed to determine if moxonidine represents a significant advancement.